Skip to main content
Premium Trial:

Request an Annual Quote

Biomarkers Going Mainstream

In a Wall Street Journal article today, columnist Sharon Begley introduces readers to the concept of biomarker tests. The hope and hype are both familiar to the scientific community but, until recently, have remained under the radar of the general public.

While Begley's article makes it clear that biomarkers are not yet ready for primetime, the question for this community is, how close are we? As this kind of information reaches consumers, questions will follow -- and it's not clear whether scientists, clinicians, and regulators have the necessary answers yet. What's needed to get on track to not only get biomarkers into mainstream medicine, but to prepare the mainstream audience for this new tool?


The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.